McKesson (NYSE:MCK) Stock Gets Price Target Increase from UBS Group

McKesson (NYSE:MCK) had its price objective hoisted by investment analysts at UBS Group from $1,200.00 to $1,250.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group‘s target price would suggest a potential upside of 16.24% from the company’s previous close.

A number of other analysts also recently weighed in on MCK. Argus increased their target price on shares of McKesson from $850.00 to $970.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Mizuho boosted their price target on shares of McKesson from $905.00 to $1,020.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 20th. TD Cowen upped their price objective on shares of McKesson from $1,006.00 to $1,200.00 and gave the company a “buy” rating in a research note on Thursday. Robert W. Baird set a $1,015.00 price objective on shares of McKesson in a research report on Thursday, August 6th. Finally, Weiss Ratings raised shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, September 4th. Fifteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, McKesson has an average rating of “Moderate Buy” and an average target price of $1,026.18.

McKesson Trading Up 0.6%

Shares of MCK stock opened at $1,075.38 on Thursday. The stock has a market cap of $125.38 billion, a price-to-earnings ratio of 27.65, a PEG ratio of 2.13 and a beta of 0.27. The stock has a 50-day moving average of $934.72 and a 200-day moving average of $866.92. McKesson has a 1-year low of $723.68 and a 1-year high of $1,121.50.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.72 by $0.96. The company had revenue of $110.96 billion during the quarter, compared to the consensus estimate of $109.90 billion. McKesson had a negative return on equity of 235.48% and a net margin of 1.12%. The firm’s revenue was up 7.5% compared to the same quarter last year. During the same period last year, the company earned $9.86 earnings per share. Sell-side analysts forecast that McKesson will post 44.71 earnings per share for the current year.

Insider Buying and Selling

In other McKesson news, EVP Francisco Fraga sold 600 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $1,050.00, for a total value of $630,000.00. Following the transaction, the executive vice president directly owned 5,064 shares of the company’s stock, valued at approximately $5,317,200. The trade was a 10.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bradley E. Lerman sold 301 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,812 shares of company stock valued at $1,794,182 over the last 90 days. Company insiders own 0.06% of the company’s stock.

Institutional Trading of McKesson

Several hedge funds have recently modified their holdings of the stock. Nvwm LLC increased its stake in McKesson by 933.3% in the third quarter. Nvwm LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 28 shares in the last quarter. Delos Wealth Advisors LLC acquired a new position in shares of McKesson during the second quarter valued at about $27,000. Trellis Wealth Advisors LLC bought a new position in shares of McKesson during the 3rd quarter worth about $32,000. Clearstead Trust LLC bought a new position in shares of McKesson during the 2nd quarter worth about $37,000. Finally, GK Wealth Management LLC bought a new position in shares of McKesson during the 3rd quarter worth about $38,000. Institutional investors own 85.07% of the company’s stock.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson reported adjusted EPS of $11.68, above analyst expectations of roughly $10.70, on revenue of $110.96 billion versus estimates of $109.9 billion. Revenue grew about 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40. Specialty-drug demand, GLP-1 distribution, higher prescription volumes and operating gains supported the outlook; McKesson also closed its $2.25 billion Precision Medicine Group acquisition, expanding its healthcare services business. McKesson Q2 2027 Earnings Call Highlights
• Positive Sentiment: Analyst sentiment was broadly constructive: TD Cowen, Leerink Partners and Evercore ISI raised price targets to $1,200, while Deutsche Bank lifted its target to $1,120. RBC also praised McKesson’s execution. TD Cowen Raises McKesson Price Target
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, retaining 5,064 shares. SEC Filing
• Negative Sentiment: RBC’s “sector perform” rating and $965 price target—despite an increase from its prior target—indicate a more cautious view and imply downside from the recent share price. RBC on McKesson’s Execution

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.